OncoMed Pharmaceuticals Inc (OMED.O) Company Profile
OncoMed Pharmaceuticals, Inc. (OncoMed) incorporated on July 19, 2004, is a clinical development-stage biopharmaceutical company. The Company focuses on discovering and developing monoclonal antibody therapeutics targeting cancer stem cells (CSCs). It utilizes its technologies to identify, isolate and evaluate CSCs; identify and/or validate multiple potential targets and pathways critical to CSC self-renewal and differentiation; and develop targeted antibody and other protein-based therapeutics that are designed to modulate these CSC targets and inhibit the growth of CSCs. The Company’s anti-cancer therapeutics include anti-DLL4 (demcizumab, OMP-21M18), Anti-DLL4/Anti-VEGF Bispecific, and Anti-Notch2/3 (OMP-59R5), Anti-Notch1 (OMP-52M51, Anti-Fzd7, Fzd8-Fc, RSPO-LGR.
Anti-DLL4 (demcizumab, OMP-21M18) is a humanized monoclonal antibody that inhibits Delta Like Ligand 4 (DLL4) in the Notch signaling pathway. The Company has completed a single-agent Phase Ia trial in advanced solid tumor patients. The Company focuses on conducting two Phase Ib combination trials of demcizumab. Anti-DLL4/anti-VEGF bispecific is a monoclonal antibody that targets and inhibits both DLL4 and vascular endothelial growth factor ( VEGF). VEGF is the target of Avastin. Anti-Notch2/3 (OMP-59R5) is a human monoclonal antibody that targets the Notch2 and Notch3 receptors.
Anti-Notch1 OMP-52M51 is a humanized monoclonal antibody targeted to the Notch1 receptor. Anti-Fzd7 OMP-18R5 is a human monoclonal antibody identified by screening against the Frizzled7 receptor (Fzd7) that binds a conserved epitope on five Frizzled receptors and inhibits Wnt signaling. OMP-18R5 is in a Phase I single-agent trial in advanced solid tumor patients. Fzd8-Fc OMP-54F28 is a fusion protein based on a truncated form of the Frizzled8 receptor ( Fzd8). RSPO-LGR ligands signal through the LGR receptor family.
The Company utilizes several robust technologies for the discovery and optimization of its antibody and protein-! based therapeutics, including multiple proprietary technologies. Its antibody technologies include Mammalian Display Technology, Bispecific Antibody Technology, Hybridoma Technology. Mammalian Display Technology utilizes flow cytometry to isolate mammalian cells expressing antibodies on the cell surface with desired characteristics from large libraries of candidate antibodies. Bispecific Antibody Technology is used to generate its anti-DLL4/anti-VEGF antibody. Hybridoma Technology is used for isolating antibodies from mice, including multiplex single-cell screening techniques.
News about OMED
A top Netflix executive is out after using the N-word
A top Netflix executive has left the company after he used the N-word in front of colleagues on more than one occasion. The streaming service's chief communications officer, Jonathan Friedland, issued an apology on Twitter Friday and said he's leavi...Read More>>>
5 Top Dividend Kings to Buy and Hold Forever
Income investors often ask "who are the dividend kings?" They're indisputably the best and the safest dividend stocks you can buy because dividend kings are companies that have increased their dividends every year for the last 50 consecutive years o...Read More>>>
Private Capital Group LLC Acquires 1,984 Shares of Novartis AG (NVS)
Private Capital Group LLC lifted its holdings in shares of Novartis AG (NYSE:NVS) by 410.8% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,467 shares o...Read More>>>
Cramer: Strength in tech and retail has 'masked' weakness in the broader market
Investors are starting to realize that massive strength in tech and retail stocks have been concealing weakness in the broader market, CNBC's Jim Cramer said Friday. ...Read More>>>
Barnes & Noble Education Inc. Aced This Q4 Report
College-textbooks vendor Barnes & Noble Education (NYSE:BNED) reported fourth-quarter results for the 2018 fiscal year on Wednesday evening and smashed Wall Street's earnings and sales estimates. Investors welcomed the good news with open arms, s...Read More>>>